Under a tenth of people eligible to benefit from GLP-1 drugs including Wegovy have access to them, caution the World Health Organization as it issues its first guidance on the drugs.
Considering in excess of 1,000,000,000 people worldwide currently living with obesity, it is urging more widespread and fairer access to GLP-1 medication.
Based on estimates, more than two billion are projected to be living with obesity by 2030 unless action is taken.
"Our latest guidance recognises that excess weight is a lifelong illness that can be managed with comprehensive and continuous treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are major obstacles to universal access to the jabs that can help people shift substantial body mass, explains the body.
Skinny Jab Shortage
Despite the current most favorable scenario, the supply of GLP-1 therapies would only suffice for approximately 100 million people – under 10% of eligible patients, according to the health organization.
The guideline urges nations and manufacturers to widen availability, through measures including voluntary licensing.
Exclusive production rights on semaglutide – the core ingredient of Novo Nordisk's Wegovy – is set to lapse in a number of nations in 2026.
How Weight-Loss Drugs Function
These medications imitate a biological compound to delay gastric emptying, curb appetite and increase feelings of fullness so users reduce food intake.
Patients typically see weight reduction in the initial weeks of commencing the weekly injections.
Research indicates people may regain a significant portion after a year of halting the treatment, as their usual hunger come back.
To be carrying excess weight elevates your likelihood for developing medical conditions, such as diabetes, heart disease, brain attack, and some malignancies.
Excess weight concerns people in every country and was responsible for millions of deaths worldwide in 2024, per the health agency.
